Surface-Modified Exosomes With PEGylated RGD for Longer Circulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting and delivering therapeutics to cancer cells and ocular neovascularization are limited by non-specific accumulation, low active-targeting functions, and short systemic half-life of exosomes, leading to suboptimal therapeutic efficacy and frequent injections.
Innovation Solution
Development of ASL-incorporated exosomes (AEx) with a synthetic anchor-spacer-ligand (ASL) conjugate that incorporates a fluorescent lipophilic boron-dipyrromethene (BODIPY) anchor, a poly(ethylene glycol) (PEG) spacer, and an RGD peptide ligand for targeted binding to integrin αvβ3, enhancing therapeutic efficacy and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exosomes are used for drug delivery to cancer cells, then biocompatibility and cell-homing ability are improved, but systemic half-life is short leading to low therapeutic efficacy
Solution Approach 1:
The patent modifies the surface properties of exosomes by conjugating PEGylated RGD peptides, changing physical and chemical parameters such as surface hydrophilicity, charge distribution, and molecular weight profile to extend circulation half-life while preserving biocompatibility
Solution Approach 2:
The patent creates a composite surface structure on exosomes by integrating multiple functional components: RGD peptide for target recognition, PEG spacer for steric stabilization and extended circulation, and lipid anchor for membrane incorporation, forming a multifunctional coating that simultaneously addresses half-life and targeting needs
2Measurement precision
If RGD peptide is coated on exosomes for targeting integrin αvβ3, then active targeting function is improved, but non-specific accumulation and short half-life persist
Solution Approach 1:
The patent introduces PEG spacer as an intermediary component between the RGD peptide and exosome surface, which mediates the interaction by providing steric protection that extends half-life while allowing the RGD peptide to maintain its targeting function to integrin αvβ3
Solution Approach 2:
The patent applies targeting ligands (RGD peptide) only at the surface of exosomes where they are needed for cell recognition, while the bulk of the exosome maintains its natural biocompatible properties, creating localized functional zones that address targeting needs without compromising overall system performance
3Reliability
If high dose exosomes are administered to overcome short half-life, then therapeutic efficacy is improved, but dosage complexity and administration frequency increase
Solution Approach 1:
By modifying the exosome surface with PEGylated RGD conjugates, the patent changes the pharmacokinetic parameters of the delivery system, extending circulation half-life and reducing the required dosage frequency and complexity of administration while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AEx demonstrate enhanced stability, targeted binding to integrin αvβ3, and improved therapeutic efficacy in cancer and ocular neovascularization models, achieving significant tumor suppression and NV reduction without distinct side effects.
Implementation Method 1
The anchor molecule can be a fluorescent lipophilic boron-dipyrromethene (BODIPY) that can incorporate into the exosome membrane
Implementation Method 2
an RGD peptide ligand for targeted binding to integrin αvβ3
Data Source
AI summary
Exosomes are disclosed that are modified to include an anti-neovascularization agent and a targeting modality that extends outwardly from a surface membrane of the exosome. Also disclosed are methods of producing and using the exosomes, for example as treatments for ocular conditions involving neovascularization.